OrthoPediatrics reports record Q3 revenue of $40.0M, up 14% YoY; raises adj. EBITDA guidance

ORTHOPEDIATRICS CORP

2023-Q3 EPS reported -$0.63 revenue$111,119,000

Total revenue $40.0M (+14% YoY); U.S. revenue $29.4M (+11%), international $10.6M (+26%).
Trauma & Deformity revenue $28.8M (+21%); Scoliosis $10.3M (+3%); Sports Med/Other $0.9M (-20%).
Net loss of $4.6M vs net income of $18.5M in prior year; adjusted EBITDA record $3.6M (vs $1.9M).
Full-year 2023 revenue guidance reiterated at $148-151M; adj. EBITDA guidance raised to $4-5M.
Consigned $3.9M of sets in Q3 (vs $6.4M in Q3 2022); cash $84.0M with no credit line drawn.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ORTHOPEDIATRICS CORP updated its the third quarter ended September 30, 2023 guidance (reaffirmed).

Period: the third quarter ended September 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

OrthoPediatrics Corp. issued a press release announcing its earnings for the quarter ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

ORTHOPEDIATRICS CORP filing history →

Source: SEC EDGAR

accession 0001425450-23-000111

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.